

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO. FILING DATE 09/424,091 02/23/2000		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO. 7544	
		RICHARD ANDREW KAY	350013-66		
7	7590 12/26/2001				
OPPENHEIMER WOLFF & DONNELLY			EXAMINER		
2029 CENTURY PARK EAST 38TH FLOOR LOS ANGELES, CA 90067			DECLOUX, AMY M		
			ART UNIT	PAPER NUMBER	

1644

DATE MAILED: 12/26/2001

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED TES DEPARTMENT OF COMMERCE Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

09/424,091 2/23/00 Kay et al. 350013=66 This is a second of the secon	Y DOCKET NO.	PPLICANT ATT	FIRST NAMED		FILING DATE	SERIAL NUMBER
	350013=66			Kay et al.	2/23/00	09/424,091
			1 _			
Amy DeCloux	EXAMINER					
	Amy DeCloux					
ART UNIT PAPER	PER NUMBER	ART UNIT				
1644	10	1644	_ [

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patent

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. **Specifically, sequences lacking SEQ ID NO: tags are disclosed on page 36, lines 9 and 11**. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicants are required to submit a CRF disk and paper copy of the sequences according to the attached "Notice to Comply with the Sequence Rules." Applicant is reminded of the sequence rules which require a submission for all sequences of more than 9 nucleotides or 3 amino acids (see 37 C.F.R. 1.821-1.825) and is also requested to carefully review the submitted specification and claims for any and all sequences which require compliance with the rules.

Any inquiry concerning this communication should be directed to Examiner Amy DeCloux, Art Unit 1644, whose telephone number is (703) 306-5821. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Applicant is given TIME PERIOD of ONE EXTENDABLE MONTH, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

December 18, 2001 Amy DeCloux, Ph.D., Patent Examiner, Art Unit 1644 David a Saunders

DAVID SAUNDERS
PRIMARY EXAMINER
ART UNIT 182 / 644

Application No.: 09/424,091

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: See attached communication.
App	olicant Must Provide:
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support (SIRA) Technical Assistance

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE